Click here to go to the previous page
Head & Neck I - Chemo-Irradiation and Salvage
Program Code:
SS-C
Date:
Monday, October 29, 2007
ABSTRACT PRESENTER(S):
Click the plus sign to see more detailed information
about each speaker.
Robert Amdur,
M.D., Professor,
University of Florida Shands Cancer Center
I have taught the eLearning course at ASTRO for the past 2 years and have many publications related to head and neck radiotherapy
|
K. Ang,
M.D., Ph.D., FASTRO, Professor,
M.D. Anderson Cancer Center
Kian Ang began his career in the field of radiation oncology at the University of Leuven in 1980. In 1984, he was recruited to the University of Texas M. D. Anderson Cancer Center where he progressed to the rank of Professor in 1990 and was awarded the Robert R. Herring Professorship in Clinical Research in 1992 and the Gilbert H. Fletcher Distinguished Memorial Chair in 1996. has served many societies in various capacities, such as President and Chair of the Board of Directors of the American Society for Therapeutic Radiology and Oncology (ASTRO) and a Trustee of the American Board of Radiology.
Kian Angs research efforts focus on developing biologically sound therapy for head and neck cancer. He has been the Principal Investigator of a Program Project Grant entitled "Modulation and Prediction of Radiation Response", which fosters interactions between laboratory and clinical scientists in developing novel therapy strategies for selective sensitization of tumors and protection of normal tissue injury. He also chairs the Head and Neck Cancer Committee of the Radiation Therapy Oncology Group. This group has completed several major randomized trials contributing to changing the standard of care for head and neck carcinomas. He has published extensively and has received various awards, medals and has given many keynote and named lectures.
|
Volker Budach, M.D., Ph.D., Dpt. for Radiation Oncology, Campus Mitte, Charité University Medicine Berlin, Germany
Paul Harari,
M.D., Professor,
University of Wisconsin School of Medicine
Dr. Paul M. Harari is the Jack Fowler Professor and Chairman of the Department of Human Oncology at the University of Wisconsin School of Medicine and Public Health. Dr. Harari earned his Bachelors degree at Tufts University (1980) and Medical degree at the University of Virginia (1984). He completed his Internal Medicine Internship at the University of California Davis and Radiation Oncology Residency Training at the University of Arizona (1990). His clinical and laboratory research focuses primarily on treatment advances for head and neck cancer patients with emphasis on the interaction of molecular growth inhibitors combined with radiation. He serves as the Principal Investigator for a series of federal and industry sponsored research grants that examine the interaction of molecular growth inhibitors with radiation. Dr. Harari has served as Chairman of the ASTRO Education Committee (2004-2008) and on the ASCO Education and Program Committees. He directed the Radiation Oncology Residency Training Program at the University of Wisconsin from 1997-2007. Dr. Harari has authored over 150 original research articles and book chapters on cancer research topics with particular emphasis on the treatment of head and neck cancer.
|
Mohit Kasibhatla, M.D., Duke University Medical Center, Durham, NC
Nancy Lee, Radiation Oncologist, Memorial Sloan-Kettering Cancer Center
Min Yao, M.D., University of Iowa, Iowa City, IA
Anamaria Yeung, M.D., University of Florida Shands Davis Cancer Center, Gainesville, FL
Susannah Yovino, M.D., University of Maryland Medical System, Baltimore, MD
MODERATOR(S):
Click the plus sign to see more detailed information
about each speaker.
Dr. Drake Brizels clinical interests include head and neck cancer, non-melanoma skin cancer, targeted therapy, and tumor physiology. His research interests include the treatment of head and neck cancer has constituted both my principal clinical focus and the framework for my research efforts since my arrival at Duke in 1987. I led an in house randomized trial which was one of the first to demonstrate that concurrent chemoradiation was more efficacious than radiotherapy alone for locally advanced head and neck cancer. Reduction of treatment induced morbidity has been a major interest of mine. I served as the principal investigator of the pivotal randomized trial of amifostine in head and neck cancer. This study established proof of priniciple for the feasibility of pharmacologic radioprotection. The FDA approved this drug for protection against radiation induced xerostomia based on this trial. Presently, I am involved in preclinical and clinical studies that are evaluating the potential role of keratinocyte growth factor for protection against radiation induced mucositis and pneumonitis. One of these is a multi-center clinical trial that is evaluating the ability of keratinocyte growth factor to diminish the severity of mouth and throat soreness that develops during chemoradiation for head and neck cancer. I have served as co-Principal Investigator of a multinational randomized trial that tested the benefit of adding the hypoxic cell cytotoxin, tirapazamine, to concurrent chemoradiation in advanced head and neck cancer. I am conducting a unique clinical trial that combines both EGFR blockade (Tarceva) and VEGF blockade (Avastin) simultaneously with our standard regimen of hyperfractionated irradiation and concurrent cisplatin in advanced head and neck cancer.
|
Madhur Garg, M.D., Montefiore Medical Center, Bronx, NY